drugset / Trial / NCT01121289

A Trial Investigating NN1218 in Subjects With Type 1 Diabetes

NCT01121289

Phase 1 Completed 26 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 diabetes.

Timeline

Start
2010-04
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin aspart Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Comparator insulin aspart Protein / enzyme biologic 0.4 iu/kg Subcutaneous